Deucravacitinib

Cat. No.: PI1609392279

Description: Deucravacitinib is a Tyrosine Kinase 2 Inhibitor. The mechanism of action of deucravacitinib is as a Tyrosine Kinase 2 Inhibitor. Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.

Product Details

CAS	1609392-27-9
Trade Names	Sotyktu
Synonyms	6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
Molecular Formula	C20H22N8O3
Molecular Weight	425.5
Technology	Synthetic

* Our products are for research use only.

Get in Touch

We’re glad to help you with your products and services demands. For any inquiry, question or recommendation, please send an email to or fill out the following form.

Name *

Phone

Email *

Address *

Products & Service of Interest *

Project Description

Verification Code *